In accordance with this, in glioblastoma patients treated with VEGFR inhibitors, an increase of FGF-2 levels was observed in correlation with tumor progression [146], suggesting that targeting FGF could be part of the treatment for glioblastomas resistant to anti-VEGF therapy [147,148]. This evidence concerns the gene FGF2 and glioblastoma.